Viable Myocardium Detected by Hybrid PET/MR and SPECT for the Prediction of the Efficacy of PCI in Patients With CTO.

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Oct 30, 2023

Keywords

ClinConnect Summary

This clinical trial is examining whether advanced imaging techniques, specifically Hybrid PET/MR and SPECT, can help identify viable heart tissue in patients with chronic total occlusion (CTO) of the coronary artery. The goal is to determine if recognizing this healthy heart muscle can predict the success of a procedure called percutaneous coronary intervention (PCI), which is used to open blocked arteries and improve heart function.

To be eligible for this trial, participants must be between 18 and 75 years old, have a completely blocked coronary artery for at least three months, and experience symptoms like chest pain. During the study, participants will undergo imaging before and six months after the PCI procedure to see if their heart function improves. This trial is currently recruiting participants and aims to provide valuable insights into how imaging can guide treatment decisions for patients with serious heart conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≧ 18 years, \< 75 years;
• • 2. complete occlusion of the coronary artery, confirmed by coronary angiography with TIMI flow grade 0, and occlusion for ≥3 months;
• • 3. presence of angina or angina-equivalent symptoms ; undergo coronary intervention;
• Exclusion Criteria:
• • 1. life expectancy \< 1 year due to non-cardiac disease;
• • 2. contraindications to SPECT/PET/MRI: pregnancy, contrast allergy, claustrophobia, history of pacemaker and ICD implantation, other ferromagnetic materials in the body;
• • 3. acute coronary syndrome within the last 3 months;
• • 4. severe valvular heart disease;
• • 5. haemodynamic instability;
• • 6. hepatic or renal insufficiency, with alanine aminotransferase (ALT) \> 3 times the upper limit of normal or glomerular filtration rate ≤ 30 mL/min;
• • 7. two or more CTO lesions;
• • 8. previous myocardial infarction.
• • 9. Others who, in the opinion o f the investigator, should not be enrolled;